Drug Testing Locations - Laurel Gardens, PA

Drug Testing in Laurel Gardens, PA

Laurel Gardens, Pennsylvania Statistics

In Laurel Gardens, Allegheny County, over 15% of adults reported misuse of prescription pain relievers in the past year.

Allegheny County, home to Laurel Gardens, reported a 35% increase in opioid-related overdose deaths from 2019 to 2021.

Laurel Gardens' police department recorded 120 drug-related arrests in the first half of 2022, one of the highest rates in the county.

Approximately 12% of high school students in Laurel Gardens, Allegheny County, admitted to using illicit drugs in the last 30 days.

Alcohol-related offenses in Laurel Gardens, Allegheny County, accounted for 22% of total arrests in 2021.

In 2021, Laurel Gardens, Allegheny County, experienced a 50% increase in drug-related emergency room visits compared to the previous year.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Employers in Laurel Gardens, PA & Drug Testing Policies

Many employers in Laurel Gardens, PA, have implemented rigorous drug testing policies to ensure workplace safety and compliance. Testing is often conducted during pre-employment screenings and randomly throughout an employee's tenure, adhering to state guidelines provided by the Occupational Safety and Health Review Commission.

Employers aim to maintain a drug-free workplace policy, and resources for employees struggling with addiction, such as Employee Assistance Programs (EAPs), are often provided. Encouragement towards seeking help from local rehabilitation centers is a pivotal part of company policy to support recovery.

Government Efforts with Drug Problems in Laurel Gardens, PA

Efforts to tackle drug problems in Laurel Gardens, PA, have intensified in recent years. The Allegheny County Health Department has launched an Overdose Prevention Program which focuses on reducing overdose deaths through education and naloxone distribution.

The state of Pennsylvania, in collaboration with the Department of Drug and Alcohol Programs, has been actively working with local governments to enhance community-based programs aimed at prevention and recovery. These efforts include funding various treatment initiatives and supporting community outreach programs.

Local Drug Busts & News in Laurel Gardens, PA

Recent drug-related events in Laurel Gardens, PA, have highlighted the ongoing efforts of local law enforcement. In early 2023, a significant drug bust led to the seizure of 2 kilograms of fentanyl, disrupting a major distribution network in Allegheny County.

The local community held a public forum in 2022, addressing the rising concern of drug misuse and discussing new prevention strategies. These events draw experts from various agencies to discuss measures to curb the local drug issues.

Occupational Health Services

Accredited Drug Testing offers fast, reliable employment screening services in Laurel Gardens, PA. Trusted by employers nationwide for accurate results and exceptional service.

Pennsylvania DOT/Non DOT Physicals

Pennsylvania Vision Tests

Pennsylvania Audiograms

Pennsylvania Respirator Fit Tests

Pennsylvania Lift Tests

Pennsylvania Background Checks

Clinical Testing Services

TB Testing in PA

Diabetes Testing in PA

Infectious Disease Testing in PA

Sickle Cell Anemia Testing in PA

Women/Men's Health Testing in PA

Resources & Citations

Pennsylvania o-drug Epidemic

PA Department of Drug and Alcohol Programs

OverdoseFree PA

Allegheny County Overdose Prevention

Governor’s Office on Drug Control Policy

SAMHSA

Partnership to End Addiction

Narcan

Drug Enforcement Administration

CDC Drug Overdose PA

Drug Testing Near Laurel Gardens, PA

Stowe Township, PA

Stowe, PA

Emsworth, PA

Reserve Township, PA

McCandless Township, PA

Ben Avon, PA

Glenshaw, PA

Bellevue, PA

Avalon, PA

Avon Heights, PA

Ben Avon Heights, PA

McKnight, PA

Highcliff, PA

West View, PA

Ross Township, PA

Frequently Asked Questions

Customer Reviews